AstraZeneca Calquence plus chemoimmunotherapy approved in EU for 1st-line mantle cell lymphoma Ruchika Sharma7 May 2025 12:30 PM ISTCambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the...
Shilpa Medicare marketing partner Amneal Pharma unveils multiple myeloma treatment Boruzu Ruchika Sharma4 April 2025 12:30 PM ISTKarnataka: Shilpa Medicare has announced that the Company's marketing partner, Amneal Pharmaceuticals, has launched BORUZU, (Bortezomib...
Biocon arm gets USFDA nod for cancer, deep vein thrombosis drugs Ruchika Sharma5 March 2025 11:30 AM ISTBangalore: Biocon Limited has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received final approvals...
USFDA approves AstraZeneca Calquence, bendamustine, rituximab combo for previously untreated mantle cell lymphoma Ruchika Sharma18 Jan 2025 1:30 PM ISTCambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in combination with...
Astrazeneca Calquence granted priority review by USFDA for previously untreated mantle cell lymphoma Ruchika Sharma5 Oct 2024 2:30 PM ISTCambridge: AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) has been accepted and granted Priority Review in...
Shilpa Medicare gets USFDA nod for Bortezomib Injection for multiple myeloma Ruchika Sharma28 Aug 2024 11:57 AM ISTKarnataka: Shilpa Medicare Ltd has announced the U.S. Food and Food Administration (USFDA) has approved the Company's second NDA...
Bristol Myers Squibb Breyanzi gets USFDA nod for Relapsed or Refractory Mantle Cell Lymphoma Ruchika Sharma31 May 2024 2:15 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi (lisocabtagene...
AbbVie plan to withdraw accelerated nods of Imbruvica in US for patients with certain types of blood cancer Ruchika Sharma7 April 2023 3:30 PM ISTIMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.
AstraZeneca Calquence gets conditional nod in China for adults with previously treated mantle cell lymphoma Ruchika Sharma26 March 2023 10:00 AM ISTMantle cell lymphoma is a rare B-cell malignancy subtype and is typically clinically aggressive with a poor prognosis.
Eli Lilly oncology unit gets USFDA nod for Jaypirca to treat mantle cell lymphoma Ruchika Sharma29 Jan 2023 4:15 PM ISTMCL is a rare blood cancer and a form of non-Hodgkin lymphoma.
Alembic Pharma bags USFDA nod for mantle cell lymphoma drug Acalabrutinib Ruchika Sharma19 Jan 2023 3:15 PM ISTAcalabrutinib Capsules are indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy...
Dr Reddy's Labs unveils cancer drug Lenalidomide in US Ruchika Sharma8 Sept 2022 2:47 PM ISTDr. Reddy's Lenalidomide Capsules are available in strengths of 2.5 mg, 5 mg, and 10 mg, each in a bottle-count size of 28, as well as 15 mg, 20 mg,...
